Ignite Creation Date:
2025-12-24 @ 11:02 PM
Ignite Modification Date:
2026-01-04 @ 11:17 AM
Study NCT ID:
NCT03442569
Status:
COMPLETED
Last Update Posted:
2025-07-01
First Post:
2018-02-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
LCCC1632
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None